Crescent Biopharma, Inc. also files under GLYC; those filings are included. Filings under CBIO by Catalyst Biosciences, Inc. (CIK 0001124105) from Aug 20, 2015 to Oct 27, 2023 belong to a different issuer and are not shown.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Brumm Joshua T | Chief Executive Officer, Director | Sell(S) | 8K | $16.71 | $131K |
| Sep 18, 2026 | McNeill Jonathan | President and COO | Sell(S) | 4K | $16.71 | $64K |
| Sep 16, 2026 | Scalzo Richard William | Chief Financial Officer | Sell(S) | 568 | $17.90 | $10K |
| Sep 16, 2026 | Pinkas Jan | Chief Scientific Officer | Sell(S) | 658 | $17.90 | $12K |
| Sep 16, 2026 | Brumm Joshua T | Chief Executive Officer, Director | Sell(S) | 2K | $17.90 | $29K |
| Sep 16, 2026 | Im Ellie Eunkyung | Chief Medical Officer | Sell(S) | 623 | $17.90 | $11K |
| Sep 16, 2026 | Lynch Ryan | See Remarks | Sell(S) | 240 | $17.90 | $4K |
| Sep 16, 2026 | Bispham Barbara Harlin | See Remarks | Sell(S) | 620 | $17.90 | $11K |
| Sep 16, 2026 | McNeill Jonathan | President and COO | Sell(S) | 731 | $17.90 | $13K |
| Jul 16, 2026 | Fairmount Funds Management LLC | Director, 10% Owner | Buy(P) | 526K | $14.50 | $7.6M |
| Jul 16, 2026 | Fairmount Funds Management LLC | Director, 10% Owner | Buy(P) | 853K | $14.50 | $12.4M |
| Jun 22, 2026 | Pinkas Jan | Chief Scientific Officer | Sell(S) | 1K | $17.99 | $23K |
| Jun 22, 2026 | McNeill Jonathan | President and COO | Sell(S) | 21K | $17.99 | $370K |
| Jun 22, 2026 | Scalzo Richard William | Chief Financial Officer | Sell(S) | 1K | $17.99 | $20K |
| Jun 22, 2026 | Brumm Joshua T | Chief Executive Officer, Director | Sell(S) | 42K | $17.99 | $761K |
| Jun 22, 2026 | Lynch Ryan | See Remarks | Sell(S) | 465 | $17.99 | $8K |
| Jun 22, 2026 | Im Ellie Eunkyung | Chief Medical Officer | Sell(S) | 1K | $17.99 | $22K |
| Jun 22, 2026 | Bispham Barbara Harlin | See Remarks | Sell(S) | 1K | $17.99 | $22K |
| Jun 2, 2026 | Violin Jonathan | Director | Grant(A) | 11K | — | $0 |
| Jun 2, 2026 | Balcom Alexandra | Director | Grant(A) | 11K | — | $0 |
| Jun 2, 2026 | Fairmount Funds Management LLC | Director, 10% Owner | Grant(A) | 11K | — | $0 |
| Jun 2, 2026 | Lubner David Charles | Director | Grant(A) | 11K | — | $0 |
| Jun 2, 2026 | Moran Susan | Director | Grant(A) | 11K | — | $0 |
| Dec 15, 2025 | Doughty Christopher Grant | Chief Business Officer | Grant(A) | 59K | — | $0 |
| Dec 15, 2025 | Doughty Christopher Grant | Chief Business Officer | Grant(A) | 15K | — | — |
| Dec 15, 2025 | Lynch Ryan | See Remarks | Grant(A) | 4K | — | — |
| Dec 15, 2025 | Brumm Joshua T | Chief Executive Officer, Director | Grant(A) | 180K | — | $0 |
| Dec 15, 2025 | Doughty Christopher Grant | Chief Business Officer | Grant(A) | 8K | — | — |
| Dec 15, 2025 | Lynch Ryan | See Remarks | Grant(A) | 34K | — | $0 |
| Dec 15, 2025 | Pinkas Jan | Chief Scientific Officer | Grant(A) | 5K | — | — |
| Dec 15, 2025 | Lynch Ryan | See Remarks | Grant(A) | 8K | — | — |
| Dec 15, 2025 | Brumm Joshua T | Chief Executive Officer, Director | Grant(A) | 10K | — | — |
| Dec 15, 2025 | Brumm Joshua T | Chief Executive Officer, Director | Grant(A) | 45K | — | — |
| Dec 15, 2025 | Scalzo Richard William | Chief Financial Officer | Grant(A) | 58K | — | $0 |
| Dec 15, 2025 | Bispham Barbara Harlin | See Remarks | Grant(A) | 72K | — | $0 |
| Dec 15, 2025 | Scalzo Richard William | Chief Financial Officer | Grant(A) | 5K | — | — |
| Dec 15, 2025 | Bispham Barbara Harlin | See Remarks | Grant(A) | 12K | — | — |
| Dec 15, 2025 | Scalzo Richard William | Chief Financial Officer | Grant(A) | 14K | — | — |
| Dec 15, 2025 | McNeill Jonathan | President and COO | Grant(A) | 78K | — | $0 |
| Dec 15, 2025 | McNeill Jonathan | President and COO | Grant(A) | 6K | — | — |
| Dec 15, 2025 | Bispham Barbara Harlin | See Remarks | Grant(A) | 6K | — | — |
| Dec 15, 2025 | McNeill Jonathan | President and COO | Grant(A) | 20K | — | — |
| Dec 15, 2025 | Im Ellie Eunkyung | Chief Medical Officer | Grant(A) | 65K | — | $0 |
| Dec 15, 2025 | Im Ellie Eunkyung | Chief Medical Officer | Grant(A) | 5K | — | — |
| Dec 15, 2025 | Im Ellie Eunkyung | Chief Medical Officer | Grant(A) | 16K | — | — |
| Dec 15, 2025 | Pinkas Jan | Chief Scientific Officer | Grant(A) | 70K | — | $0 |
| Dec 15, 2025 | Pinkas Jan | Chief Scientific Officer | Grant(A) | 18K | — | — |
| Dec 8, 2025 | McNeill Jonathan | President and COO | Grant(A) | 173K | — | $0 |
| Dec 8, 2025 | Brumm Joshua T | Chief Executive Officer, Director | Grant(A) | 346K | — | $0 |
| Dec 4, 2025 | Harwin Peter Evan | Director, 10% Owner | Buy(P) | 131K | $13.41 | $1.8M |
| Dec 4, 2025 | Harwin Peter Evan | Director, 10% Owner | Buy(P) | 1.4M | $13.41 | $18.2M |
| Jul 16, 2025 | Pinkas Jan | Chief Scientific Officer | Grant(A) | 142K | — | $0 |
| Jun 23, 2025 | Harwin Peter Evan | Director, 10% Owner | Grant(A) | 9K | — | $0 |
| Jun 23, 2025 | Moran Susan | Director | Grant(A) | 9K | — | $0 |
| Jun 23, 2025 | Violin Jonathan | Director | Grant(A) | 9K | — | $0 |
| Jun 23, 2025 | Balcom Alexandra | Director | Grant(A) | 9K | — | $0 |
| Jun 23, 2025 | Lubner David Charles | Director | Grant(A) | 9K | — | $0 |
| Jun 13, 2025 | BVF GP Holdings LLC | 10% Owner | Other(J) | 304K | — | — |
| Jun 13, 2025 | BVF GP Holdings LLC | 10% Owner | Other(J) | 557K | — | — |
| Jun 13, 2025 | BVF GP Holdings LLC | 10% Owner | Other(J) | 56K | — | — |
| Jun 13, 2025 | BVF GP Holdings LLC | 10% Owner | Other(J) | 258K | — | — |
| Jun 13, 2025 | BVF GP Holdings LLC | 10% Owner | Other(J) | 26K | — | — |
| Jun 13, 2025 | BVF GP Holdings LLC | 10% Owner | Other(J) | 657K | — | — |
| Aug 8, 2024 | Siren, L.L.C. | 10% Owner | Sell(S) | 261K | $0.19 | $50K |
| Aug 7, 2024 | Siren, L.L.C. | 10% Owner | Sell(S) | 61K | $0.18 | $11K |
| Aug 6, 2024 | Invus Public Equities Advisors, LLC | 10% Owner | Sell(S) | 56K | $0.18 | $10K |
| Aug 5, 2024 | Invus Public Equities Advisors, LLC | 10% Owner | Sell(S) | 165K | $0.19 | $31K |
| Aug 2, 2024 | Siren, L.L.C. | 10% Owner | Sell(S) | 286K | $0.20 | $57K |
| Aug 1, 2024 | Siren, L.L.C. | 10% Owner | Sell(S) | 64K | $0.22 | $14K |
| Jul 30, 2024 | Siren, L.L.C. | 10% Owner | Sell(S) | 757K | $0.22 | $167K |
| Jul 29, 2024 | Siren, L.L.C. | 10% Owner | Sell(S) | 364K | $0.24 | $87K |
| Jul 26, 2024 | Siren, L.L.C. | 10% Owner | Sell(S) | 258K | $0.24 | $62K |
| Jun 21, 2024 | Rock Edwin | Chief Medical Officer | Buy(P) | 115K | $0.27 | $31K |
| Jun 20, 2024 | Rock Edwin | Chief Medical Officer | Buy(P) | 190K | $0.25 | $48K |
| Jun 18, 2024 | Hahn Brian M. | SVP Finance, CFO | Buy(P) | 18K | $0.25 | $4K |
| May 1, 2024 | Goldberg Mark Alan | Director | Grant(A) | 40K | — | $0 |
| May 1, 2024 | Pearson Timothy R | Director | Grant(A) | 40K | — | $0 |
| May 1, 2024 | King Rachel K. | Director | Grant(A) | 40K | — | $0 |
| May 1, 2024 | Andrews Patricia S | Director | Grant(A) | 40K | — | $0 |
| May 1, 2024 | Jackson Scott Thomas | Director | Grant(A) | 40K | — | $0 |
| May 1, 2024 | Junius Daniel M | Director | Grant(A) | 40K | — | $0 |
| May 1, 2024 | Koenig Scott | Director | Grant(A) | 40K | — | $0 |
| Mar 29, 2024 | Junius Daniel M | Director | Grant(A) | 5K | $3.00 | $16K |
| Mar 29, 2024 | Goldberg Mark Alan | Director | Grant(A) | 5K | $3.00 | $14K |
| Mar 29, 2024 | King Rachel K. | Director | Grant(A) | 3K | $3.00 | $10K |
| Jan 12, 2024 | Rath Chinmaya | SVP and Chief Business Officer | Grant(A) | 250K | — | $0 |
| Jan 12, 2024 | Johnson Bruce S | SVP & Chief Commercial Officer | Grant(A) | 250K | — | $0 |
| Jan 12, 2024 | Semerjian Harout | Chief Executive Officer, Director | Grant(A) | 695K | — | $0 |
| Jan 12, 2024 | Rock Edwin | Chief Medical Officer | Grant(A) | 250K | — | $0 |
| Jan 12, 2024 | Hahn Brian M. | SVP Finance, CFO | Grant(A) | 250K | — | $0 |
| Dec 29, 2023 | Andrews Patricia S | Director | Grant(A) | 5K | $2.36 | $12K |
| Dec 29, 2023 | King Rachel K. | Director | Grant(A) | 4K | $2.36 | $10K |
| Dec 29, 2023 | Goldberg Mark Alan | Director | Grant(A) | 6K | $2.36 | $14K |
| Sep 30, 2023 | King Rachel K. | Director | Grant(A) | 7K | $1.50 | $10K |
| Sep 30, 2023 | Goldberg Mark Alan | Director | Grant(A) | 9K | $1.50 | $14K |
| Sep 30, 2023 | Andrews Patricia S | Director | Grant(A) | 8K | $1.50 | $12K |
| Sep 22, 2023 | Rock Edwin | Chief Medical Officer | Buy(P) | 30K | $1.38 | $42K |
| Sep 21, 2023 | Rock Edwin | Chief Medical Officer | Buy(P) | 35K | $1.38 | $48K |
| Jun 1, 2023 | Koenig Scott | Director | Option exercise(M) | 21K | — | $0 |
| Jun 1, 2023 | Koenig Scott | Director | Option exercise(M) | 21K | $0.60 | $13K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Crescent Biopharma, Inc., SEC CIK 0001253689. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under CBIO and shows every filing by that issuer (also filed as GLYC). Earlier filings under the same symbol by another issuer are left out.
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-19. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for CBIO